Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2


Перейти к контенту

Главное меню:

Welcome to BESPONSA® | BESPONSA®, Besponsa: Uses, Side Effects, Benefits/Risks | Drugs.com, Inotuzumab ozogamicin - Wikipedia, BESPONSA™ (inotuzumab ozogamicin) | R/R B-Cell ALL , BESPONSA - inotuzumab ozogamicin, BESPONSA 1 mg powder for concentrate for solution for , NICE to reassess Pfizer’s leukaemia drug Besponsa , Besponsa | Pfizer UK, EU nod for Pfizer’s Besponsa - PharmaTimes.
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. Medical information for Besponsa including therapeutic indications, usage and dosage instructions, plus benefits and possible risk factors..
Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. BESPONSA ® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520. There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. The National Institute for Health and Care Excellence will reassess Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia.. Our contribution to the UK spans research and development, supporting education, charitable donations and collaborations with organisations across the healthcare spectrum..
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню